Autolus Therapeutics (Autolus Therapeutics) 3-Year EBITDA Growth Rate

: 33.90% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Autolus Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-0.19.

During the past 3 years, the average EBITDA Per Share Growth Rate was 33.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Autolus Therapeutics was 33.90% per year. The lowest was -45.80% per year. And the median was -1.30% per year.

Competitive Comparison

For the Biotechnology subindustry, Autolus Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics 3-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's 3-Year EBITDA Growth Rate falls into.

Autolus Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Autolus Therapeutics (NAS:AUTL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Autolus Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.